Global Partners L.P. (GLP)
NYSE NYSE Primary 
This top stock-picker spotted Nvidia and GLP-1s early — and made over 200%. Here's what he's buying now.
Citrini Research founder James Van Geelen identifies potential big money trends and stakes his claim far ahead of the crowd.
Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference
Novo Nordisk CEO Mike Doustdar said 2026 will be the year of "price pressure" as more GLP-1 supply enters the market and pricing deals take effect. Bristol Myers Squibb CEO Chris Boerner said the company has the potential to deliver up to 10 new products by the end of the decade.
Novo Nordisk CEO flags 1.5 million US users of compounded GLP-1 drugs
Novo Nordisk CEO Mike Doustdar said on Monday as many as 1.5 million patients in the U.S. may be using compounded versions of blockbuster GLP-1 drugs, underscoring how cheaper, unapproved alternatives have captured a significant share of demand for obesity treatments.
The GLP-1 Blockbuster Maker Widens Its Lead as the Diversified Healthcare Giant Posts Steady Growth
Eli Lilly (NYSE: LLY) and Johnson & Johnson (NYSE: JNJ) both delivered strong third-quarter results, but their earnings revealed two fundamentally different healthcare businesses.
Novo Nordisk and Eli Lilly can both gain GLP-1 market share this year, says Citi's Meacham
Geoff Meacham, Citi analyst, joins 'Fast Money' to talk what the year ahead holds for competition in the obesity drug market.
Hims & Hers: Looking Beyond GLP-1s To The Next Phase Of Global Growth
Hims & Hers Health is significantly undervalued, with the market underestimating its growth potential and international expansion opportunities. Geographical and product expansion, vertical integration, and a unique personalized offering position HIMS to regain historical growth rates by 2026 and beyond. Management targets substantial margin expansion, aiming for adjusted EBITDA margins of at least 20% by 2030, with marketing spend expected to decrease.
Novo Nordisk launches first oral GLP-1 weight loss pill in the US
Novo Nordisk (NYSE:NVO) has made its Wegovy pill, the first oral GLP-1 treatment for weight loss, broadly available to patients in the United States. The launch marks a new development in obesity treatment, offering a once-daily pill alternative to weekly injections that have dominated the market.
First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.
American patients can now receive the first-ever GLP-1 pill for weight loss from Novo Nordisk, marking a new chapter of obesity treatment in the U.S. The cash prices of the drug, called the Wegovy pill, are among the lowest on the market, ranging from $149 to $299 per month.
Viking Therapeutics: A Wide-Open Oral GLP-1 Market
Viking Therapeutics is positioned favorably in the oral GLP-1 obesity drug race, with strong Phase 2 results for VK2735. VKTX's oral candidate achieved 12.2% weight loss at the highest dose in 13 weeks, matching or exceeding peers' metrics and showing potential for further improvement. Management will focus Phase 3 dosing on 20-75 mg, balancing efficacy and tolerability while the injectable 78-week Phase 3 Vanquish trial is underway.
FDA approves first GLP-1 pill for obesity from Novo Nordisk
FDA approves first GLP-1 pill for obesity from Novo Nordisk
The FDA has approved the first GLP-1 pill for weight loss, clearing a tablet from Novo Nordisk
Novo Nordisk said it plans to start selling the new pill in the U.S. soon after the new year, with a cash price of $149 a month for the starting dose.
Can Intuitive Surgical Weather GLP-1 Drag on Bariatric Surgery?
Intuitive Surgical grapples with a GLP-1-driven bariatric slump but leans on strong general surgery gains and rising da Vinci 5 adoption.
